C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 20.6 PLN -1.67% Market Closed
Market Cap: 1.1B PLN

Intrinsic Value

The intrinsic value of one CLN stock under the Base Case scenario is 14.81 PLN. Compared to the current market price of 20.6 PLN, Celon Pharma SA is Overvalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CLN Intrinsic Value
14.81 PLN
Overvaluation 28%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation History
Celon Pharma SA

What is Valuation History?
Ask AI Assistant
What other research platforms think about CLN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CLN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Celon Pharma SA.

Explain Valuation
Compare CLN to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CLN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Celon Pharma SA

Current Assets 103.2m
Cash & Short-Term Investments 21m
Receivables 55.5m
Other Current Assets 26.6m
Non-Current Assets 368.2m
Long-Term Investments 26.2m
PP&E 315.7m
Intangibles 2.7m
Other Non-Current Assets 23.5m
Current Liabilities 54.4m
Accounts Payable 10.9m
Accrued Liabilities 21.3m
Other Current Liabilities 22.2m
Non-Current Liabilities 27.8m
Long-Term Debt 6.5m
Other Non-Current Liabilities 21.3m
Efficiency

Free Cash Flow Analysis
Celon Pharma SA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Celon Pharma SA

Revenue
228.6m PLN
Cost of Revenue
-71.5m PLN
Gross Profit
157.1m PLN
Operating Expenses
-249.9m PLN
Operating Income
-92.8m PLN
Other Expenses
-29.3m PLN
Net Income
-122.1m PLN
Fundamental Scores

CLN Profitability Score
Profitability Due Diligence

Celon Pharma SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Gross Margin is Increasing
Declining Net Margin
22/100
Profitability
Score

Celon Pharma SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

CLN Solvency Score
Solvency Due Diligence

Celon Pharma SA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Negative Net Debt
69/100
Solvency
Score

Celon Pharma SA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CLN Price Targets Summary
Celon Pharma SA

Wall Street analysts forecast CLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLN is 25.94 PLN with a low forecast of 16.16 PLN and a high forecast of 35.7 PLN.

Lowest
Price Target
16.16 PLN
22% Downside
Average
Price Target
25.94 PLN
26% Upside
Highest
Price Target
35.7 PLN
73% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CLN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CLN stock?

The intrinsic value of one CLN stock under the Base Case scenario is 14.81 PLN.

Is CLN stock undervalued or overvalued?

Compared to the current market price of 20.6 PLN, Celon Pharma SA is Overvalued by 28%.

Back to Top